logo
Bad Botox? Six cases of botulism on the South Shore tied to possible Botox injections

Bad Botox? Six cases of botulism on the South Shore tied to possible Botox injections

Boston Globe06-06-2025
South Shore Health declined to answer questions about whether they were treating suspected cases or how many they were seeing, referring instead to the Department of Public Health.
Advertisement
However Jason Tracy, chief medical officer at the hospital, said generally that patients are given a presumptive diagnosis made off of their clinical presentation of symptoms and history of recent injections.
Related
:
From there, the hospital would involve both the Department of Public Health and the Centers for Disease Control, which has an anti-toxin that it provides on a case-by-case basis. The anti-toxin helps slow the progression of symptoms, but does not reverse them, and so hospitals typically also provide supportive measures.
'This is quite rare,' Tracy said. 'This is different than a food-borne botulism type case. It's not as though there is a lot body of literature to refer clinicians to to give prognosis and historical elements and time courses for what to expect.'
South Shore Hospital in Weymouth.
Pat Greenhouse/Globe Staff
Use of botulinum toxin — commonly known by the popular brand name Botox — for cosmetic procedures is widely
Advertisement
Cosmetic treatments with botulinum toxin use doses much lower than for medical treatments, said Dr. Mathew M. Avram, director of the Mass General Hospital Dermatology Laser and Cosmetic Center.. With regulated, FDA-approved products in a healthy adult, the amount of the toxin is so small that it is exceedingly rare for it to cause botulism.
'I've never seen a patient or had a colleague of mine at Mass General or elsewhere that has told me they have had a case of this. It is not something that happens normally,' Avram said. 'Someone would have to go outside the realm of what you would typically inject to encounter these issues, for a typical patient.'
Beyond injecting far too much, poor administration technique or using counterfeit products can increase risks.
'We have seen instances where injectors have used counterfeit products or products they developed on their own,' Avram said. 'These are unsafe practices that can harm patients.'
According to the advisory, botulism results when the botulinum toxin circulates in the blood. Symptoms including double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, and difficulty breathing. Such symptoms are sometimes followed by muscle weaknesses, which can progress over the course of hours or days.
Advertisement
DPH has asked clinicians to warn patients interested in these cosmetic injections of the potential risks, and is advising patients to receive injections only from licensed providers.
'If someone has had a botox injection and has had those symptoms they should seek medical attention,' Tracy said. 'I don't want to create worry but someone having visual changes, slurred speech and difficulty swallowing — they should not ignore it."
The reports are only the latest Botox problems to surface in the South Shore. In November, 38-year-old Rebecca Fadanelli, was arrested and charged for selling counterfeit Botox out of Skin Beauté Med Spa in Easton and Randolph.
Jessica Bartlett can be reached at
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer
FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer

Yahoo

timean hour ago

  • Yahoo

FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer

Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food and Drug Administration (FDA) to treat breast cancer. The treatment is aimed at patients with oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), oestrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer who have previously undergone endocrine-based therapy. The Prescription Drug User Fee Act (PDUFA) action date is set for 5 June 2026. Vepdegestrant is an investigational, oral bioavailable PROteolysis TArgeting Chimera (PROTAC) medication designed to degrade oestrogen receptors. It is being developed collaboratively by Arvinas and Pfizer as a potential monotherapy option. The submission was based on results from VERITAC-2, a randomised, global Phase III study that compared vepdegestrant against fulvestrant. Patients were randomly assigned in a 1:1 ratio to receive either vepdegestrant, administered orally once daily on a continuous 28-day schedule, or fulvestrant, which was given intramuscularly. 43% of the patients in the trial had detectable ESR1 mutations. Progression-free survival (PFS), measured both in patients with ESR1 mutations and across all trial participants, served as the primary endpoint evaluated through blinded independent central review. Overall survival (OS) remains an important secondary endpoint. Arvinas chairperson, CEO and president John Houston stated: 'Patients often face limited treatment options after first-line treatment and vepdegestrant demonstrated improved progression-free survival in patients with ESR1-mutated ER+/HER2- advanced breast cancer. 'With the efficacy and favourable tolerability seen in VERITAC-2, we believe vepdegestrant, if approved, has potential to be a best-in-class treatment option for patients in the second-line ESR1-mutant setting.' In August 2025, Pfizer raised its full-year profit forecast, driven by robust sales of its heart disease medication Vyndaqel (tafamidis) and the blood thinner Eliquis (apixaban), among other products. "FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic

Yahoo

time2 hours ago

  • Yahoo

GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic

-- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea. The drugmaker's shares climbed 1% in London on the news. The company is looking to new infectious disease products, including its recently launched respiratory syncytial virus vaccine, to offset expected revenue declines from top-selling medicines and looming patent expirations in its HIV portfolio. Gepotidacin is already approved in the U.S. under the brand name Blujepa for treating a common urinary tract infection in women and adolescent girls. The FDA is expected to decide in December on its use for uncomplicated urogenital gonorrhoea, which could offer patients an oral alternative to existing injectable treatments. Separately, GSK and Germany's CureVac last week resolved a long-running patent dispute with Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) over mRNA vaccine technology used during the COVID-19 pandemic. The settlement follows BioNTech's June agreement to acquire CureVac in an all-stock deal worth $1.25 billion to advance work on mRNA-based cancer therapies. Under the settlement, CureVac and GSK will receive $740 million and single-digit percentage royalties on future U.S. sales of COVID-19 vaccines, CureVac said. GSK's share amounts to $370 million, including $50 million to adjust terms from a 2024 licence agreement that expanded their pandemic-era partnership. If BioNTech's takeover of CureVac is completed, related mRNA litigation outside the U.S. will also be resolved, with GSK receiving an additional $130 million and royalties extended to non-U.S. sales. CureVac said the acquisition remains on track under the agreed terms. GSK said it still has separate patent cases against Pfizer and BioNTech in the U.S. and Europe, which are unaffected by this settlement. Related articles GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic USPS blocks major vape distributor over unregulated product shipments - Reuters Exclusive: Opendoor CEO Wheeler breaks silence, EMJ's Eric Jackson calls for more Sign in to access your portfolio

Sugar cookies sold in 20 states recalled for potential wood contamination: See map
Sugar cookies sold in 20 states recalled for potential wood contamination: See map

Indianapolis Star

time5 hours ago

  • Indianapolis Star

Sugar cookies sold in 20 states recalled for potential wood contamination: See map

Hundreds of cases of sugar cookies sold at Target are being recalled for potential contamination by a "foreign material," according to a notice posted to the Food and Drug Administration's website. The voluntary recall for the Favorite Day Bakery Frosted Sugar Cookies was issued on July 22 by Give and Go Prepared Foods Corp. in Canada, according to the FDA. Favorite Day is a private label brand sold at Target. In total, 803 cases are being recalled due to the potential foreign contamination. The cookies, which could potentially contain wood, were distributed across 20 different states and Washington, D.C., the notice stated. The recall is classified as a Class II recall, meaning the product "may cause temporary or medically reversible adverse health consequences," according to the FDA. A press release was not issued for the recall, but as of Sunday, Aug. 10, the recall is ongoing. Target did not immediately respond to a request for comment from USA TODAY on Aug. 10. The cookies were sold in the following states and districts: The recalled cookies, Favorite Day Bakery Frosted Sugar Cookies, 10 count, were distributed by Target and produced in Canada. The cookies are a part of Lot 25195, with the UPC number 85239-41250 3. The packs of cookies have varying Best By Dates, as that is determined by when the retailer removed the cookies from the freezers, according to the notice.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store